In the past few years, including the pandemic hit 2020, a record number of partnerships were signed between global pharma groups and Chinese startups, signifying how far the country has opened up its healthcare market.

In a CEO interview session at the Financial Times Global Pharmaceutical and Biotechnology Conference, Sarah Neville, FT's Global Health Editor, discussed with John V. Oyler, Founder, and CEO of BeiGene about how China successfully expands its pharma capabilities beyond manufacturing into innovation and market access.

John described China as a dynamic participant in the global drug discovery and development field. He mentioned that the changes in the last decade happened as a result of government policies and regulatory reforms that encouraged innovations and China's active participation in the global system.